Blinatumomab for leukemia relapse after a stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests the drug blinatumomab for people whose B-cell acute lymphoblastic leukemia (B-ALL) has come back after a stem cell transplant. The goal is to see if blinatumomab can safely treat the relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 65 years old or younger.
- Your vital signs are stable (like steady blood pressure and heart rate).
- You do not have a severe infection.
- You do not have moderate or severe graft-versus-host disease (a transplant complication).
- Your heart, liver, and kidneys are working well (no organ failure).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called blinatumomab for people with B-ALL whose leukemia has come back at a very low level (detected only by sensitive testing) after a stem cell transplant. The goal is to see if blinatumomab can clear these remaining leukemia cells and prevent a full relapse.
This trial tests if a targeted drug, blinatumomab, can help prevent leukemia from coming back after a stem cell transplant. It is for people with high-risk B-cell acute lymphoblastic leukemia who have achieved remission but are at high risk of relapse.
This study tests if blinatumomab, an immunotherapy drug, can prevent B-cell acute lymphoblastic leukemia (B-ALL) from coming back in people who have already had a donor stem cell transplant. You may qualify if you had a relapse before transplant or had a positive minimal residual disease test, and if you are now in complete remission after the transplant.
This trial tests whether the drug blinatumomab, given after a stem cell transplant, can help prevent high-risk B-ALL from coming back. It is for people who have already had a transplant and meet certain health criteria.
This trial tests whether a drug called blinatumomab can clear leftover leukemia cells in children with B-cell acute lymphoblastic leukemia (B-ALL) who still have traces of disease after standard treatment. It aims to reduce the chance of relapse.
This trial tests blinatumomab, an immune therapy, in young people with B-cell acute lymphoblastic leukemia (B-ALL) after their transplant or when they are getting ready for transplant. The goal is to lower the chance of the leukemia coming back by targeting remaining leukemia cells.
Hear when a new Acute B-cell Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.